Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Fundraising

HelloSign

HelloSign Raises $40M in Series C

San Francisco, CAMay 1, 20242 min read
Employees
150+

HelloSign Raises $40M in Series C


HelloSign has successfully raised $40M in a Series C at a $300M valuation led by IVP, Greylock Partners.


Company Overview


HelloSign is a Enterprise Software company headquartered in San Francisco, CA, founded in 2010 with 150+ employees.


Electronic signature platform


Fundraising Details


  • Amount Raised: $40M
  • Round Type: Series C
  • Valuation: $300M
  • Date: 2024-05-01
  • Investors: IVP, Greylock Partners

About HelloSign


Electronic signature platform The company is positioned in the Enterprise Software sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: San Francisco, CA
  • Founded: 2010
  • Team Size: 150+
  • Industry: Enterprise Software

What This Means


This funding round demonstrates strong investor confidence in HelloSign's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Enterprise Software sector continues to attract significant investment as companies innovate to meet evolving market demands. HelloSign's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $300M valuation marks an important milestone for HelloSign, positioning the company among notable players in the Enterprise Software industry.


Looking Ahead


With this new capital, HelloSign is well-positioned to execute on its growth strategy and continue building innovative solutions in the Enterprise Software space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-05-01. For more information about HelloSign, visit their headquarters at San Francisco, CA.

Company Info

Headquarters
San Francisco, CA
Founded
2010
Team Size
150+

Topics

Fundraising(2912)Enterprise Software(383)Series C(300)HelloSign

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free